StockCall Scrutinizes Alexion Pharma and Celgene: Biotech Stocks Offers Healthy Returns

Tue Feb 19, 2013 8:05am EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link

LONDON,  February 19, 2013  /PRNewswire/ --

Biotech sector provides some very good investment opportunities. The sector has
good bets in large cap as well as small cap segments. However, these companies
have high risk profile as well as most of the stocks derive their value from
their drug candidates. Various contingency factors like delay in the clinical
trial or lack of the FDA approval can instantly send a stock into a tizzy. On
the other hand, any positive occurrence has the similar impact in the upward
direction. Celgene Corporation (NASDAQ: CELG) stock is on the upward trajectory
following the approval of its multiple myloma drug. Similarly, Alexion
Pharmaceuticals Inc. (NASDAQ: ALXN) reported strong results. Its stock is
performing well on the strength of its healthy portfolio and impressive array of
potential drug candidates. StockCall reviewed the solar industry and chose
Alexion Pharmaceuticals and Celgene for its technical coverage. These free
reports can be seen for free at

Celgene Grows with Robust Drug Pipeline

Celgene Corporation recently received approval for its new multiple myloma drug,
Pomalyst. The drug has shown good results and is expected to be successful in
the market. The company focuses on developing its drug pipeline and augmenting
its revenue. Celgene is one of the most prominent companies in its field.
Register for today's free analysis on Celgene Corp. at   

The biotech's stock grew 25 percent on a YTD basis and its bullish stance is
likely to continue as the company works towards creating new drugs. For FY2013,
the company expects its revenue to increase 11 percent and it expects its
revenue to touch  $12 billion  per annum by 2017. Though, the company does not
pay any dividend, it has a robust share repurchase program and bought back  $2
billion  worth of stock in 2012. Celgene still has authorization to purchase up
to  $1.8 billion  worth of stock and it is likely to make good use of this
authorization, bringing extra value to its investors.

Celgene has a healthy portfolio of products and a robust development pipeline.
Among its top performers is Revlimid, which continues to perform well. However,
other drugs like Thalomid are in a declining phase. The company now looks
forward to get approval for its new drug Abraxane. Celgene Corp. offers a good
investment opportunity with long-term potential.

Alexion Pharma Reports Higher Net Sales

Alexion Pharmaceuticals reported 41 percent increase in its net product sales
for the fourth quarter of FY2012. Its net adjusted income jumped 52 percent to 
$122.3 million. Similarly, its full year results also showed an encouraging
trend. The company currently has five drug candidates in its product pipeline.
For 2013, Alexion expects its net product revenue to be in the range of  $1.49
billion  and  $1.505 billion. The stock is up 6 percent in the past 52 weeks.
Download the free research on Alexion Pharmaceuticals Inc. by signing up now at   

Alexion also has strong share buyback program. Late last year it authorized 
$400 million  worth of shares repurchase program. The company's sales superstar
Soliris is likely to keep performing well as it does not face any imminent
challenge from competing drugs. However, the company also needs to build up
diversified portfolio as it is currently dependent on Soliris' performance
alone. Though, investment in an orphan drug company is slightly risky, but
returns may sometimes justify the risk.

About is a financial website where investors can have easy, precise and
comprehensive research and opinions on stocks making the headlines. Sign up
today to talk to our financial analyst at


Contact Person:William T. Knight, Email:, Contact Number:
+1(646)396-9857 (9:00 am EST - 01:30 pm EST)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.